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Abstract 
 
 Transforming Growth Factor-β (TGF-β) regulates a variety of biological effects, 
including cellular proliferation, dependent on the cellular context. There is growing 
evidence that TGF-β regulates numerous pathways independent of Smad, including the 
PI3K/Akt pathway. Therefore, since FoxO is downstream of PI3K/Akt, we examined the 
role of TGF-β on the post-translational regulation of FoxO family members. It was found 
that TGF-β increased the phosphorylation of FoxO1, 3a, and 4, as well as the cytoplasmic 
localization of FoxO1 in fibroblasts via the PI3K/Akt pathway.  In addition, since Akt and 
FoxO members can induce phosphorylation and transcription of p27kip1 (a cyclin 
dependent kinase inhibitor), respectively, we examined both the post-translational and 
transcriptional regulation of p27kip1 by TGF-β in fibroblasts. p27kip1 phosphorylation 
increased following TGF-β addition, resulting in cytoplasmic localization in fibroblasts 
over time. p27kip1 mRNA expression decreased following TGF-β treatment in fibroblasts, 
however, we were unable to show the decrease was dependent on PI3K or FoxO4. 
Therefore, the results demonstrated that TGF-β regulates the FoxO group post-
translationally via the PI3K/Akt pathway, and FoxO group functionality through 
transcription and post-translational modifications of p27kip1 in fibroblasts.  
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CHAPTER 1-Literature Review 
1.1 TGF-β  
1.1.1 TGF-β Family 
Transforming Growth Factor-β (TGF-β) is a large superfamily of cytokines that 
include TGF-βs, Activins, Inhibins, Bone Morphogenic Proteins (BMPs), Growth 
Differentiation Factors (GDFs), and Müllerian Inhibiting Substance (Akhurst and Hata, 
2012; Horowitz et al., 2004; Katz et al., 2013; Moustakas and Heldin, 2005). All family 
members have in common a conserved cysteine residue motif (Akhurst and Hata, 2012). 
TGF-βs direct a large array of cellular processes including embryonic development, cell 
migration, growth inhibition, epithelial-mesenchymal transition (EMT), invasion, 
extracellular matrix remodeling and immune system modulation (Akhurst and Hata, 
2012; Bakin et al., 2000; Horowitz et al., 2004). TGF-βs act in a cell type specific 
manner; inhibiting cellular proliferation in non-transformed epithelial, endothelial and 
hematopoietic cells and induction of cellular proliferation in mesenchymal cells (Shin et 
al., 2001; Massagué, 2008). These opposing functions of TGF-β, contributes to the 
complexity of this growth factor. 
TGF-βs are found in all multicellular organisms (Akhurst and Hata, 2012) and 
there are three isoforms of TGF-βs in mammals that share a high degree of homology: 
TGF-β1, -β2 and -β3.  TGF-β1 is the most abundant and most studied isoform (Katz et 
al., 2013).   A variety of cells including platelets (Katz et al., 2013) and stromal cells 
(Colletta et al., 1990) secrete inactive TGF-β as a latent homodimeric polypeptide bound 
to a latent complex protein.  It only becomes an active ligand when the complex is 
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cleaved proteolytically by metalloproteases MMP-9 and MMP-2 (Yu and Stamenkovic, 
2000), reactive oxygen species (ROS; Barcellos-Hoff & Dix, 1996), Thrombospondin-1 
(Schultz-Cherry and Murphy-Ullrich, 1993), and/or acidic pH (Lyons et al., 1988). Once 
activated the ligand can bind to receptors and initiate cell signalling.  
 
1.1.2 TGF-β Receptors 
Activated TGF-β ligand binds to a serine/threonine kinase transmembrane 
receptor and initiates cytoplasmic signalling pathways. The functional receptor is a 
heterotetramer of two type I receptor molecules and two type II receptor molecules (Katz 
et al., 2013). In mammals, the entire TGF-β superfamily consists of 7 type I receptors 
(Activin-like kinases or ALKs) and 5 type II receptors and different combinations of 
receptors can occur depending on the ligand bound (Katz et al., 2013). For TGF-β1, -β2 
and -β3 ligands, it is the TGF-β type II receptor (TβRII) and the TGF-β type I receptor 
(TβRI; also referred to as ALK5) that is involved in eliciting the downstream signalling 
pathways (Miyazono et al., 2010). Endoglin and β-Glycan (type III TGF-β receptor) are 
co-receptors that bind ligands through the type I and type II receptors (Katz et al., 2013) 
to regulate ligand binding and signalling.  
TGF-β ligand initially binds to the TβRII and results in the constitutively active 
type II receptor recruiting and phosphorylating/activating the type I receptor. The 
association of the two receptors triggers cross-phosphorylation of the Gly-Ser-rich (GS) 
domain of TβRI by TβRII, thereby activating the type I receptor kinase activity. This 
allows for the docking of substrates propagating signalling pathways, such as the Smad 
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pathway (Katz et al., 2013; Moustakas and Heldin, 2005; Bakin et al., 2000; Yi et al., 
2005; Miyazono et al., 2012).  Active receptor complexes are sequestered by the cell and 
initiate downstream signalling while receptor complexes absent of ligand are internalized 
and recycled back to the plasma membrane (Dore et al., 2001). TGF-β receptor 
complexes are removed from the membrane via clathrin-mediated endocytosis (Figure 1) 
and membrane rafts. Clathrin-mediated endocytosis of TGF-β receptors targets 
localization to the early endosome. This location is necessary for TGF-β Smad signal 
transduction (Penheiter et al., 2002). Membrane raft endocytosis of TGF-β receptors 
antagonistically promotes the association of inhibitory Smads with the receptor complex 
(DiGuglielmo et al., 2003), preventing TGF-β signalling.  
 
1.2 Smad Pathway 
The canonical signalling pathway of TGF-β is the Smad pathway (Figure 1; Katz 
et al., 2013; Miyazono et al., 2012). There are three classes of Smads: Regulatory Smads 
(r-Smads), which include Smad-1, -2, -3, -5, -8; the common mediator Smad-4 (co-
Smad); and inhibitory Smads (i-Smads) Smad-6, -7 (Katz et al., 2013; Miyazono et al., 
2012). Smad-2 and Smad-3 are direct substrates of TGF-β receptors and activin receptors, 
and Smad-1, -5, -8 for bone morphogenic protein receptors (Moustakas et al., 2001).  
Smad-2 and Smad-3 are recruited to the TGF-β receptor complex by SARA (Smad 
anchor for receptor activation; Tsukazaki et al., 2016). For Smad2/Smad3 
phosphorylation to occur, the SARA/Smad/TGFβ receptor complex must be internalized  
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Fig. 1 Canonical TGF-β Smad signalling pathway. A depiction of clathrin-mediated 
endocytosis of TGF-β receptor complexes and the mechanism involved in Smad 
signalling.  
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to the early endosome (Penheiter et al., 2002).  Following phosphorylation by TβRI, 
pSmad-2 /3 associates with Smad-4 and dissociates from SARA, thereby mediating 
nuclear translocation (Massagué 2008; Miyazono et al. 2012; Moustakas & Heldin 2005; 
Shin et al. 2001; Yi et al. 2005; Tsukazaki et al. 2016). R-Smads and co-Smads shuttle 
between the nucleus and cytoplasm, although this mechanism is not well understood. 
Recently a study by Wilkes et al., (2015) suggests that the trafficking protein SNX9 
(Sorting Nexins) promotes nuclear import of phosphorylated Smad-3 following TGF-β 
stimulation by binding pSmad3 to Imp8 and Impβ (importins) respectively, enabling it to 
move through the nuclear pore machinery.  Nuclear Smad complexes activate specific 
genes with the help of DNA-binding cofactors and co-repressors (Katz et al., 2013). 
Antagonistically, i-Smads block the association of r-Smads and co-Smad and thereby 
impede gene activation (Katz et al., 2013; Miyazono et al., 2012). In general, the Smad 
pathway is a well studied factor in the TGF-β signalling pathway. 
 
1.3 Non-Smad TGF-β Signalling Pathways 
The Smad pathway has been extensively studied with regards to TGF-β, however, 
it generated the question of how one simplified pathway could elicit all the diverse 
cellular functions of the large TGF-β family, let alone cell specific effects (Zhang, 2009; 
Moustakas and Heldin, 2005; Derynck and Zhang, 2003). Previously, it has been 
suggested that TGF-β promotes the activity of several other signalling pathways such as 
ERK, JNK, and p38 mitogen activated protein kinase (MAPK; Engel et al., 2000; Hong et 
al., 2011; Suzuki et al., 2007). As well, it has been reported that phosphatidylinositol-3-
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OH kinase, RhoGTPases (cdc42/Rac1), Pak2, Akt and c-abl, to name a few, can be 
activated by TGF-β and in a cell type specific manner independent of Smads (Bakin et 
al., 2000; Katz et al., 2013; Miyazono et al., 2012; Yi et al., 2005; Hong et al., 2011; 
Wilkes et al., 2005; Suzuki et al., 2007). There is some dispute in the literature whether 
or not these signalling pathways are truly Smad independent and it is still poorly 
understood whether or not these alternative pathways cross talk with or regulate the Smad 
pathway (Katz et al., 2013; Hough et al., 2012) and that they are truly independent of 
Smads (Moustakas and Heldin, 2005; Yi et al., 2005). Accumulated findings in the 
literature suggest three mechanisms by which non-Smad signalling proteins respond to 
TGF-β: 1) Smad function is modified directly by non-Smad signalling pathways, 2) 
Smads directly interact and modulate the activity of other signalling pathways and 3) 
TGF-β receptors directly interact or phosphorylate non-Smad proteins. The first two 
mechanisms suggest a cross-talk between the Smad and non-Smad pathways, whereas the 
last mechanism is independent and therefore the non-Smad proteins would not affect the 
function or signal of Smads and vice versa (Moustakas and Heldin, 2005). A direct link 
between TGF-β receptors and the cytoplasmic effector molecules, other than Smads, is 
not completely understood, and requires further investigation.  
 
1.3.1 TGF-β-induced Ras/Erk signalling pathway activation 
One example of a Smad-independent TGF-β signalling pathway involves Ras/Erk. 
Ras is a large superfamily of G-proteins, which include the Rho and Rab families of 
proteins, having the common feature that they have GTPase activity (Robbins et al., 
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1992). Ras is typically activated by receptor tyrosine kinases (RTKs), which most often 
leads to cellular proliferation or differentiation. Ras is highly implicated in cancer and 
mutated, constitutively active Ras can lead to uncontrolled cell growth (Bos, 1989; 
Campbell and Der, 2004). In the RTK pathway, binding of growth factors to the RTKs 
leads to dimerization and activation of the receptors, followed by auto- and trans-
phosphorylation of tyrosine residues in the cytoplasmic domain of the RTK (Schlessinger, 
2000; McKay and Morrison, 2007). The phosphotyrosine residues of RTK recruit and 
phosphorylate Shc (Src homology domain 2 containing), which then recruits the Grb2 
(growth factor receptor binding protein 2)/Sos complex to the plasma membrane. Sos can 
then activate Ras by catalyzing the exchange of GDP for GTP. Active Ras in its GTP 
bound state can activate a Map kinase (MAPK) cascade by binding Raf (MAP3K), which 
then activates MEK1 (MAP2K) and finally Erk (MAPK; Ravichandran, 2001). It was 
first suggested that the ERK/MAPK pathway could be activated by TGF-β from 
observations of fast activation of p21Ras in rat intestine or mink lung epithelial cells 
(Mulder and Morris, 1992; Yan et al., 1994). In the above epithelial cells the rapid GTP 
loading of Ras in response to TGF-β may cause the recruitment of Raf and lead to the 
activation of Erk through MEK1. The fast activation of Erk by TGF-β has also been 
observed in epithelial cells (Hartsough and Mulder, 1995), breast cancer cells (Frey and 
Mulder, 1997) and fibroblasts (Mucsi et al., 1996). When the response of Erk activation 
to TGF-β is delayed, an indirect Smad related response has been suggested. In reports 
where activation has occurred within 5-10 minutes of TGF-β stimulation, it is comparable 
to the activation of Erk by EGF and therefore Smad-independent (Simeone et al., 2001; 
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Olsson et al., 2001).  It is important to note that publications referring to the rapid 
responses (<30 minutes) initiate from a single lab and have not been replicated by others.  
Although TGF-β type I and type II receptors are classified as serine-threonine 
kinases, it has been reported that TβRII can autophosphorylate at three tyrosine residues: 
Y259, Y336, and Y424 (Lawler et al., 1997). Alternatively, one study suggests that Src, a 
non-RTK, can phosphorylate TβRII on Y284, which can then serve as a docking site for 
Grb2 and Shc, allowing for the bridging of TGF-β activation of the MAPK pathway 
(Galliher and Schiemann, 2007). However, several earlier studies failed to show any 
phospho-tyrosine residues on the type I or type II TGF-β receptors (Luo and Lodish, 
1997; Carcamo et al., 1994), indicating more evidence is required.  
Shc plays an essential role in TGF-β-induced Erk activation, as transfection of 
siRNA silencing Shc diminishes this response (Zhang, 2009). Moreover, Erk activation is 
important for EMT, an essential process necessary for embryonic development and 
implicated in tumor metastasis (Thiery, 2003; Lee et al., 2006). In late tumorigenesis, 
TGF-β has been implicated in inducing EMT and tumor growth through both smad-
dependent and smad-independent effects (Derynck and Akhurst, 2007; Massagué, 2008). 
TGF-β-stimulated Erk regulates genes required for disassembly of cell adherens 
junctions, remodeling of integrin-based cell-matrix adhesion and promote cell motility, all 
essential requirements of EMT and tumorigenisis (Zavadil et al., 2001).  It has been 
reported that the reduction of ShcA and Grb2 expression (by siRNA), leaves mammary 
epithelial or mammary tumor cells unresponsive to EMT induced by TGF-β, halting 
invasion and migration (Galliher-Beckley and Schiemann, 2008; Northey et al., 2008). 
Moreover, Erk can phosphorylate and inhibit Smad activity, which may explain how 
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oncogenic Ras can override TGF-β-mediated growth arrest in cancer cells and elicit TGF-
β as tumor promoting (Kretzschmar et al., 1997; Funaba et al., 2002).  In stark contrast, a 
study by Suzuki et al. (2007), found that TGF-β stimulated Ras and Erk activity in 
mesenchymal cultures but not epithelial cells, and that Ras activation was not required for 
Smad2 and Smad3 phosphorylation or nuclear localization (Suzuki et al., 2007). Other 
studies (Hough et al., 2012; Blanchette et al., 2001) have shown that Ras is not necessary 
for Erk activation and that Erk has no effect on Smad nuclear localization and actually 
increases Smad signalling.  Conflicting reports make it difficult to determine the complete 
picture regarding TGF-β and the Ras/Erk pathway, however, evidence suggests that in 
response to TGF-β the Ras/Erk pathway may follow a Smad-independent function or it 
can cross talk with the Smad pathway, depending on the cellular context.  
 
1.3.2 TGF-β-induced PI3K Activation  
1.3.2.1 PI3K 
The phosphatidylinositol-3-OH kinase (PI3K) pathway is involved in cell 
proliferation, growth, metabolism, glucose homeostasis, survival and motility (Shin et al., 
2002; Kato et al., 2006). There are three classes of PI3Ks: class I PI3K, which is divided 
into IA and IB and primarily generate PIP3 as part of receptor mediated signalling 
cascades (Katso et al., 2001), class II PI3Ks are generally involved in membrane 
trafficking and receptor internalization (Engelman et al., 2006) and class III PI3Ks are 
involved in vesicle trafficking and crosstalk with class I (Backer, 2008). For my study, I 
will be focusing on the class I PI3Ks and will refer to them as PI3K.  
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PI3Ks are heterodimers consisting of catalytic and regulatory subunits (Carracedo 
and Pandolfi, 2008; van der Heide et al., 2004). The regulatory subunit of PI3K IA, 
termed p85, typically binds to tyrosine-phosphorylated membrane receptors through its 
SH2 domains and then recruits p110 the catalytic subunit to produce active PI3K 
(Carracedo and Pandolfi, 2008; Katso et al., 2001). Once activated, PI3K locates lipid 
substrates (Figure 2) and phosphorylates the 3’-hydroxy group of the inositol ring of 
phosphatidylinositol in PIP2 (phosphatidylinositol 4,5 biphosphate) to generate PIP3 
(phosphatidylinositol 3,4,5 triphosphate; van der Heide et al., 2004). PIP3 recruits a 
variety of proteins containing either a FYVE finger (a double-zinc-binding domain named 
after four cysteine rich proteins from which it was found; FAB1, YOTB, Vac1, EEA1) or 
pleckstrin homology (PH) domains, to the plasma membrane, affecting their localization, 
conformation and activity (Carracedo and Pandolfi, 2008; Gaullier et al., 1998).  For 
example, hepatocyte growth factor-regulated tyrosine kinase (predominantly localized to 
early endosomes) and phosphatidylinositol-dependent kinase 1 (PDK1; activates Akt) 
contain FYVE and PH domains, respectively (Pullan et al., 2006; Carracedo and Pandolfi, 
2008) and are both recruited to the plasma membrane by PIP3.  
The PI3K pathway has been reported to be associated with TGF-β mediated EMT 
and migration and can be activated by TGF-β in various cell types (Bakin et al., 2000; 
Kato et al., 2006; Shin et al., 2001; Runyan et al., 2004; Wilkes et al., 2005; Hough et al., 
2012).  PI3Ks are widely known to be activated by RTKs and growth factor stimulation 
such as insulin, platelet derived growth factor receptors (PDGF), and nerve growth factor 
(Carracedo and Pandolfi, 2008; Yi et al., 2005). The most established pathway 
downstream of PI3K is the Akt pathway (Figure 2), but more recently it has been reported  
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Fig. 2 Receptor Tyrosine Kinase mediated PI3K/Akt signalling pathway. A 
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that p21-activated kinase-2 (Pak2) can be activated by PI3K following TGF-β stimulation 
(Wilkes et al., 2005). This occurred in a cell type specific manner independent of Smads  
 (Wilkes et al., 2005), supporting the reported non-Smad pathway hypothesis referred to 
previously.   
 
1.3.3 TGF-β-induced PI3K/Pak2 pathway 
The p21-activated kinases (Paks) are divided into two subfamilies and were first 
found to be effectors of p21-Rho GTPases. The two subfamilies consist of group I, Pak1, 
2 and 3, and Group II, Pak4, 5, and 6. All family members bind GTP-bound Rho family 
members at the amino-terminal p21-binding domain (PBD). The Cdc42 and/or Rac1 
family members have been shown to bind to and activate group I Paks, including Pak2, an 
important serine/threonine kinase upstream of ERK. (Radu et al., 2014).  
Pak2 activation occurs primarily in response to stresses such as radiation or serum 
starvation, and can regulate downstream Erk through Raf and Mek1 (Eblen et al., 2002). 
Several studies by Wilkes et al. have elucidated TGF-β specific activation of Pak2 via 
TGF-βR/PI3K (Wilkes et al., 2005; Wilkes et al., 2003).  They initially found that Pak2 
was activated by TGF-β in a Smad-2 and Smad-3 independent manner only in fibroblasts, 
and not in epithelial cells. This was significant in that this highlighted TGF-β cell type 
specific regulation of a pathway in one cellular context only and independently of Smads. 
It was also shown that Pak2 activation by TGF-β was dependent on CDC42/rac1 and it 
created a proliferative response in fibroblasts (Wilkes et al., 2003). Follow-up studies 
found that the Pak2 activation by TGF-β is PI3K-dependent and that PI3K independently 
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regulates both Pak2 and Akt and is spatially upstream of Pak2 (Wilkes et al., 2005). They 
determined that PI3K activation was dependent on TGF-β kinase activity, but the p85 and 
p110 regulatory subunits of PI3K was not directly phosphorylated by TGF-β receptors I 
or II (Wilkes et al., 2005). Wilkes and Leof, 2006, also determined that unlike the 
activation of Smad2 and Smad3, TGF-β activation of PI3K does not require endocytosis 
(Wilkes and Leof, 2006; Wilkes et al., 2005), offering a differentiating mechanism for 
Smad-dependent and Smad-independent TGF-β pathways. 
Very little is known about the mechanism for TGF-β receptor binding and 
transduction to the regulatory subunits of PI3K, however, it has been reported that TGF-β 
induced the non-receptor tyrosine kinase Fak binding to the p85 regulatory subunit of 
PI3K in a cell type specific manner. Fak acts as a signalling scaffold and it could help 
explain why fibroblasts can activate the non-smad pathways, Pak2 and Akt (Hong et al., 
2011). However, since epithelial cells also express Fak, there must be other players 
regulating this signalling pathway.  
 
1.4 PI3K/Akt Pathway 
The canonical PI3K pathway involves the activation of Akt, an important 
serine/threonine kinase implicated in several forms of cancer. Activated PI3K recruits 
serine/threonine kinases PDK1 and Akt (Protein Kinase B), both containing PH domains, 
to the plasma membrane (Carracedo and Pandolfi, 2008; Pullan et al., 2006). PIP3 
binding activates PDK1, which phosphorylates and partially activates Akt (Figure 2). A 
second enzyme(s), referred to as “PDK2”, also phosphorylates Akt to stimulate full 
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activity (Manning and Cantley, 2007; Guertin et al., 2006; Jacinto et al., 2006). Active 
Akt then leaves the plasma membrane and then transmits the signal initially elicited by 
PI3K (Carracedo and Pandolfi, 2008). PTEN (Phosphatase and Tensin Homolog) 
negatively regulates the PI3K pathway (Figure 2) by dephosphorylating PIP3 at the 3’ 
position and abrogating Akt binding and activation, therefore also its signal (Carracedo 
and Pandolfi, 2008; van der Heide et al., 2004), providing an important off switch.  
Akt, or formerly Protein Kinase B (PKB), is a serine/threonine kinase belonging 
to the AGC family of protein kinases, structurally related to Protein Kinase A (PKA), 
Protein Kinase G (PKG) and Protein Kinase C (PKC; van der Heide et al., 2004). There 
are three isoforms of Akt (Akt1/PKBα, Akt2/PKBβ, Akt3/PKBγ) containing three 
functionally distinct domains (van der Heide et al., 2004; Manning and Cantley, 2007): an 
N-terminal domain, a catalytic domain, and a C-terminal regulatory hydrophobic motif 
(van der Heide et al., 2004). The pleckstrin homology domain responsible for the 
recruitment of Akt to the plasma membrane, has high affinity for PIP3, and is found 
within the N-terminus domain. The catalytic kinase domain and the C-terminal domain 
share an 85-90% homology between all three Akt isoforms and activation of Akt depends 
on the phosphorylation of threonine/serine residues located within these two domains 
(Liu et al., 2014; Mundi et al., 2016).  
Akt is phosphorylated/activated by PDK1 and PDK2 at phosphorylation sites 
thr308 and ser473, respectively (positions are with respect to Akt1 isoform; Shin et al., 
2001). Once activated, Akt detaches from the plasma membrane and translocates to the 
cytosol and nucleus (Figure 2), where it phosphorylates serine or threonine residues on a 
variety of target proteins (van der Heide et al., 2004). Akt has many functions, dependent 
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on its target proteins, and can be inhibitory or stimulatory. It promotes cell survival by 
inactivating proapoptotic factors GSK3β, Bad and Caspase 9 (van der Heide et al., 2004; 
Shin et al., 2002). It also promotes cell cycle progression and gene transcription by 
inhibiting GSK3β and modulating cellular localization of ForkheadO group of 
transcription factors and p27kip1 (Shin et al., 2002).  TGF-β-induced PI3K/Akt regulation 
has been reported to be important for EMT (Bakin et al., 2000), which suggests a two-
armed model for the TGF-β signalling by PI3K, through the Pak2 pathway (Hough et al., 
2012), as well as Akt.  
1.5 FoxO Family 
As previously stated, Akt phosphorylates the group O Forkhead (FoxO) 
transcription factors.  FoxOs belong to the Forkhead family of transcription factors with 
all members containing a 100-amino acid Forkhead domain, responsible for DNA binding 
(Shin et al., 2001; Essaghir et al., 2009). FoxOs were first discovered in Caenorhabditis 
elegans as Daf-16, a transcription factor regulated by Akt (Burgering and Kops, 2002; 
Shin et al., 2002). Mutations in Daf-16 created a forked-head phenotype in C. elegans 
during larvae dauer formation thus the nomenclature (Ogg et al., 1997; Shin et al., 2001). 
FoxOs have since been identified in other organisms including zebrafish, Drosophila, 
mice, rats and humans (van der Heide et al., 2004). The mammalian orthologs of Daf-16 
are FoxO1 (previously called FKHR), FoxO3a (previously called FKHRL1), FoxO4 
(previously called AFX), and FoxO6, all comprise the Forkhead Box O group (Shin et al., 
2001; Essaghir et al., 2009). FoxO1, 3a and 4 are ubiquitously expressed at different 
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levels depending on the tissue, whereas FoxO6 is expressed only in the central nervous 
system (Anderson et al., 1998; Jacobs et al., 2003), and was not included in this study. 
FoxO expression and activity are controlled by several posttranslational 
modifications such as phosphorylation, acetylation, methylation and ubiquitination 
(Huang and Tindall, 2007; Tzivion et al., 2011). Each modification uniquely regulates 
FoxO activity, whether by degradation or physical localization of the protein within the 
cell.  A negative or positive effect on FoxO activity depends not only on the modification 
type, but also the specific regulator (Huang and Tindall, 2007).  FoxOs are activated by 
JNK (c-Jun N-terminal kinase) and MST1 (Mammalian Ste20-like kinase) during 
oxidative stress and translocate FoxO to the nucleus to induce genes involved in stress 
defence (Huang and Tindall, 2007; Wang et al., 2005). AMPK (AMP-activated protein 
kinase) phosphorylation of FoxO, during nutrient stress, targets genes involved in energy 
metabolism and stress resistance.   In contrast, negative regulators of FoxO re-locate it 
from the nucleus to cytoplasm. Akt is an important negative regulator of FoxO, however, 
SGK (serum and glucocorticoid-regulated kinase), CK1 (Casein Kinase 1) DYRK1A, 
ERK, and Iκκ (Iκβ kinase) are other negative regulators of FoxO (Liu et al., 2008). The 
target phosphorylation sites of FoxO by these regulators differs from one another, as well 
as the phosphorylation sites targeted by Akt (Huang and Tindall, 2007), allowing for 
differential FoxO modulated regulation.  
FoxOs can induce cell growth arrest and apoptosis, but are blocked from these 
functions when phosphorylated by Akt (Essaghir et al., 2009). All mammalian orthologs 
of FoxO contain three Akt phosphorylation sites (T32, S253, S315; numbered relative to 
FoxO3a) and a Nuclear Localization Signal (NLS) within the forkhead domain (Carter 
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and Brunet, 2008; Shin et al., 2001; Essaghir et al., 2009; van der Heide et al., 2004; 
Greer and Brunet, 2005; Huang and Tindall, 2007). The preferred Akt phosphorylation 
site (S253) is located within the NLS, and T32 and S315 are located N- and C-terminally 
outside of the forkhead domain, respectively (Huang and Tindall, 2007; Obsilova et al., 
2005; Greer and Brunet, 2005). Unphosphorylated FoxOs are predominantly localized in 
the nucleus where they activate target genes containing a FoxO-recognition element 
(FRE). While active they can induce cell death by directing transcription of FasL, Bim 
and Trail or inhibit the cell cycle through expression of p27kip1 and p21waf1 (Carter and 
Brunet, 2008; Shin et al., 2002; Essaghir et al., 2009). Once phosphorylated by Akt, 
FoxOs are recognized by 14-3-3 shuttling proteins that bind the now phosphorylated Akt 
sites (S253 and T32) and translocate FoxOs from nucleus to cytoplasm, where they are 
sequestered and can be targeted for ubiquitination and degradation by proteasomes 
(Essaghir et al., 2009; van der Heide et al., 2004; Shin et al., 2001). The 14-3-3 proteins 
act as a chaperone protein and in part masks the NLS allowing for the movement of FoxO 
from nucleus to cytoplasm (Obsilova et al., 2005; Greer and Brunet, 2005). The “inactive 
state” of FoxO in the cytoplasm can also be rapidly reversed, for example with the 
phosphatase PP2A (Yan et al., 2008), allowing FoxO to return to the nucleus where it can 
again activate transcription of genes involved in numerous functions, such as cell cycle 
regulation. 
1.6 Cell Cycle Regulation 
As previously stated, Akt and FoxO are both implicated in the regulation of 
cellular proliferation and growth, by influencing factors involved in the cell cycle 
	   18	  
(Manning and Cantley, 2007; Huang and Tindall, 2007; Greer and Brunet, 2005; 
Burgering and Kops, 2002) The cell cycle is a complex and tightly controlled process, 
resulting in two identical daughter cells.  It is the basis for the growth and proliferation of 
cells. Such an important process follows a highly regulated sequence of events with 
several checkpoints and regulatory proteins to ensure a proper functioning cell (Schafer, 
1998). Failure to do so could lead to a multitude of diseases, including tumorigenesis.  
The cell cycle encompasses 4 phases: G1, S, G2, and M (mitosis). DNA replication and 
cell division into two daughter cells occur during S phase and M phase, respectively. In 
between these two phases are the Gap phases; G1, where the cell expands and prepares 
for DNA synthesis in S phase, and G2, where the cell prepares for M phase. Cells that are 
not actively dividing are in a senescent phase called G0. In the presence of growth 
factors, senescent cells leave G0 and enter G1 (Williams and Stoeber, 2012; Schafer, 
1998). Each phase has specific stopping points called checkpoints where sensor 
mechanisms detect incomplete or aberrant cell cycle events and can trigger effectors 
necessary for cell cycle arrest until the problem is resolved or apoptosis is initiated 
(Williams and Stoeber, 2012)   Cyclin dependent kinases (cdk’s) and cyclin proteins 
catalyze the progression through the phases of the cell cycle (Schafer, 1998; Williams and 
Stoeber, 2012), and are important mediators of the cell cycle.   
Cdk’s are serine/threonine protein kinases that are activated at specific points in 
the cell cycle by phosphorylation on threonine and tyrosine residues (Malumbres, 2014; 
Schafer, 1998; Williams & Stoeber, 2012). The kinase activity of cdk is regulated by 4 
mechanisms; binding to cyclins, activation/inactivation by phosphorylation on different 
threonine and tyrosine residues, and inactivation by binding of inhibitory molecules 
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(Malumbres, 2014; Schafer, 1998).  Cdks are inactive as a monomer and require binding 
to cyclin to increase their enzymatic activity. It is the cdk-cyclin complexes that allow 
cell cycle progression to occur (Vervoorts and Lüscher, 2008). Cyclins are temporally 
expressed by the cell at specific points in the cell cycle to ensure that cdks can only be 
activated at certain times (Vervoorts and Lüscher, 2008). Different cdk-cyclin complexes 
occur during different phases of the cell cycle and some cdks can bind multiple cyclins 
allowing for substrate specificity (Malumbres, 2014)  For example, cyclin D-CDK4, 
cyclin D-CDK6, and cyclin E-CDK2 complex promote progression through the G1/S 
restriction point, committing the cell to DNA synthesis. Cyclin A-CDK2 initiates S phase, 
and cyclin B-CDK1 regulates progression through G2 and initiating mitosis (Williams 
and Stoeber, 2012; Planas-Silva and Weinberg, 1997; Nigg, 2001). Inhibition of these 
cyclin-cdk complexes halts cell cycle progression at any point.  
The Ink4 and Cip1/Kip1 families are effector proteins that inhibit Cyclin/cdk 
complexes. The Ink4 family, p16, p15, p18 and p19, interact primarily with cyclin D/cdk 
4,6 complexes, during G1 phase. The Cip/Kip family, p21cip1/waf1, p27kip1 and p57kip2, are 
less specific as they can bind all G1 and S cyclin/cdk complexes (Reynisdottir et al., 
1995). When active, the Ink4 and Cip/Kip inhibitors cause G1 or G2 arrest in response to 
antiproliferative agents and DNA damage (Schafer, 1998; Malumbres, 2014), to prevent 
downstream genetic errors from occurring.  
 
	   20	  
1.7 Cyclin Dependent Kinase Inhibitor, p27kip1 
p27kip1 is classified as a tumour suppressor and a cyclin-dependent kinase inhibitor 
(CDKi; Dijkers et al., 2000). It is a part of the Cip/Kip family of CDKi’s, composed of 
p21cip1/waf1, p27kip1 and p57kip2. All contain a homologous amino-terminal domain 
comprising cyclin and cdk binding regions, in order to bind cyclin-cdk complexes and 
interfere with their catalytic activity (Reynisdottir and Massague, 1997; Vervoorts and 
Lüscher, 2008). Target complexes for p27kip1 include cyclin D-cdk4/6 and cyclin E-cdk2, 
both found in late G1 phase, and cyclin A-cdk2 found at the G1/S transition and 
throughout S phase (Reynisdottir and Massague, 1997). p27kip1 inhibits these complexes 
and halts cell cycle progression (Roy and Banerjee, 2015; Reynisdottir et al., 1995; 
Dijkers et al., 2000). Upregulation of p27kip1 is linked to cell cycle arrest in G0/G1 by 
interacting with these cyclin-cdk complexes (Dijkers et al., 2000), contributing to its title 
as a tumour suppressor.  
Having such an integral role in cell cycle regulation, p27kip1 is highly regulated at 
both gene expression and post-translationally. p27kip1 gene expression is regulated by the 
binding of transcription factors and adapter proteins to the promotor site of p27kip1. There 
are several forkhead transcription factor-binding sites in the p27kip1 promotor, suggesting 
that p27kip1 is a target site for FoxO family members. Studies have found that p27kip1 
mRNA and protein is greatly elevated following FoxO3a and FoxO4 activation (Dijkers 
et al., 2000; Medema et al., 2000). Post-translational modification of p27kip1 by its 
phosphorylation at several sites also plays a pivotal role in its regulation. Phosphorylation 
of p27kip1 at T157 and T198, followed by binding to 14-3-3 proteins has been shown to 
shuttle p27kip1 from the nucleus to the cytoplasm, where it is targeted for ubiquitin 
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degradation (Liang et al., 2002; Shin et al., 2002; Motti et al., 2004). Relocalization to the 
cytoplasm renders p27kip1 incapable of binding cyclin/cdk complexes and therefore allows 
cell cycle progression (Viglietto et al., 2002). It has been found that the cellular 
localization of p27kip1 in some tumor cells is associated with poor clinical prognosis 
(Vervoorts and Lüscher, 2008), and therefore cellular localization of p27kip1 plays an 
important role on its function.  
 
1.8 Hypothesis and Objectives 
TGF-β regulates a variety of biological effects including cellular proliferation. It has 
been shown to inhibit proliferation in epithelial cells and promote proliferation in 
mesenchymal cells. Studies by Wilkes et al., 2005, have reported that TGF-β regulates the 
Pak2 pathway via PI3K in fibroblast cells and not epithelial cells, independently of 
Smads.  The canonical Smad pathway is well understood, but growing evidence supports 
Smad-independent TGF-β pathways, including the PI3K/Akt pathway. Since TGF-β 
reportedly activates the PI3K/Akt pathway (Bakin et al., 2000; Miyazono et al., 2012; Yi 
et al., 2005; Hong et al., 2011; Wilkes et al., 2005; Kato et al., 2006; Hough et al., 2012), 
and FoxO is downstream of Akt, and they can induce transcription and phosphorylation 
of p27kip1, respectively, I examined the role of TGF-β regulation of FoxO group members 
and p27kip1 in fibroblast cells. 
Hypothesis: 
I hypothesized that TGF-β regulates the FoxO group of transcription factors post-
translationally via the PI3K/Akt pathway in fibroblast cells. It is further hypothesized that 
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TGF-β regulates p27kip1 both at the transcriptional and post-translational levels in 
fibroblasts.  
Objectives: 
The following objectives were proposed to verify the hypothesis: 
1) Determine phosphorylation of individual FoxO group members by PI3K/Akt in 
fibroblast cells following TGF-β addition using Western blotting. 
2) Compare cytoplasmic localization of FoxO group transcription factors before and 
after TGF-β stimulation in fibroblast cells using immunohistochemistry and 
confocal microscopy. 
3) Determine the regulation of phosphorylation and nuclear-cytoplasmic shuttling of 
p27kip1 by Akt following TGF-β stimulation in fibroblast cells by using Western 
blotting and immunohistochemistry, respectively.  
4) Evaluate the change of PI3K/Akt directed p27kip1 gene expression, via FoxO4, 
before and after TGF-β addition in fibroblast cells by qRT-PCR.
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CHAPTER 2-Materials and Methods 
 
2.1 Cell Culture 
AKR-2B cells were grown in 10% (v/v) Fetal Calf Serum (FCS; PAA 
Laboratories, Etobicoke, ON, Canada) in high glucose Dulbecco’s Modified Eagle 
Medium (DMEM; LifeTechnologies, Carlsbad, USA). Cells were maintained at 37°C in 
an incubator containing 5% CO2/air. Cells were passaged at approximately 80% 
confluence for 18-20 serial passages (approximately 2 months) before discarding and new 
stock was thawed from liquid nitrogen.  
 
2.2 Western Blotting 
Following trypsinization and removal of cells from T175 flasks, AKR-2B cells 
were plated in six well plates at a final density of 3x105 cells/well in 10% FCS in DMEM. 
Cells were allowed to attach for 24 hours. Growth media was removed and cells were 
serum deprived in 0.1% Newborn Calf Serum (NBCS; LifeTechnologies, Carlsbad, USA) 
in DMEM for 18 to 20 hours prior to experimentation.  Cells were treated with 2 ng/mL 
of TGF-β1 for indicated time points up to 6 hours. LY294002 (LifeTechnologies, 
Carlsbad, USA) was diluted to a concentration of 10 µM (stock of 10 mM in DMSO) to 
inhibit PI3K. AKTVIII (Calbiochem; EMD Biosciences, La Jolla, CA, USA) was diluted 
to a concentration of 1 µM (1 mM stock in DMSO) to selectively inhibit AKT1 and 
AKT2.    TGF-β receptor inhibitor (LY364947; Tocris Bioscience, Ellisville, MO, USA) 
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was diluted to a concentration of 0.5 µM (1 mM stock in DMSO) to inhibit the TGF-β 
Type I receptor kinase. Inhibitors were added 30 minutes prior to TGF-β addition. 
Following treatments, cells were washed three times in ice cold PBS and lysed in 60 µl of 
RIPA [10X PBS, 1X complete protease inhibitor (Roche Diagnostics, Mannheim, 
Germany), 1% Triton X-100, 50 mM Tris-HCl (pH 7.4), 50 mM β-Glycerophosphate, 50 
mM Sodium Fluoride, 0.1% SDS, 0.1 µM Sodium Orthovanadate, 5 mM EDTA, 75 ng/µl 
PMSF (Sigma-Aldrich, St. Louis, MO, USA)].  All buffers and salts were purchased from 
EM Science (Merck Chemical; Darmstadt, Germany) unless otherwise stated. Cell lysates 
were centrifuged at 21,000xg at 4°C for 10 minutes. Supernatants were separated and 
stored at -80°C. Lysate total protein concentrations were determined using a BCA assay 
(Pierce/ThermoFisher) with a standard curve generated with a BSA/RIPA standard and 
measured using a Polarstar Optima plate reader (BMG Labtechnologies, Durham, NC, 
USA).  Equivalent amounts of protein from each sample of total cellular lysate were 
separated in an 8.5% or 12% polyacrylamide gel and transferred to PVDF (Immobilon-P; 
EMD Millipore, Billerica, MA, USA) or Nitrocellulose (BioTrace NT; Pall Corp., 
Pensacola, FL, USA) membrane prior to antibody detection of specified protein. PVDF 
membranes were blocked in Blotto Buffer 5% (w/v) Non-fat dry milk in TBST [10 mM 
Tris-HCL pH 7.4, 150 mM NaCL, 0.1% (v/v) Tween-20], and nitrocellulose membranes 
were blocked in 5% BSA/TBST, each for one hour, then incubated overnight at 4° in 
primary antibody, diluted in the appropriate blocking buffer.  Primary antibodies used 
include Phospho-FoxO1/3a (Thr24/Thr32; Cell Signalling #9464), FoxO1 (C29H4; Cell 
Signalling #2880), Phospho-FoxO3a (Ser318/321; Cell Signalling #9465), Phospho-
FoxO4 (Ser193; Cell Signalling #9471), β-actin(AC-15; Sigma A5441), α-tubulin 
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(11H10; Cell Signalling #2125), Phospho-p27Kip1 (T198; R&D systems), p27Kip1 
(sx53G8.5; Cell Signalling #3698). Membranes were washed 5 times for 5 minutes each 
in TBST and incubated for one hour at room temperature in either Goat anti-Rabbit IgG 
(Cell Signalling Technology, Danvers, MA, USA) or Goat anti-Mouse IgG (Santa Cruz 
Biotechnology; Santa Cruz, CA, USA) secondary antibodies in either Blotto Buffer 
(PVDF membrane) or 5% BSA/TBST (nitrocellulose membrane) at a 1:15 000 dilution. 
Membranes were then washed 5 times for 5 minutes each in TBST before incubated for 5 
minutes with Supersignal West Pico Chemiluminscent Substrate (Pierce/ThermoFisher 
Scientific; Rockford, IL, USA) and then exposed to film (Hyperfilm; GE Healthcare 
Biosciences, Piscataway, NJ, USA) and developed.  Multiple exposures were obtained 
from each membrane to ensure data was collected from within the linear response range 
of the film. 
 
2.3 Immunocytochemistry 
AKR-2B cells were plated at a concentration of 2x104 cells/well in each well of a 
4 chamber-slide (Lab-Tek; ThermoFisher Scientific, Rochester, NY, USA) and allowed 
to attach for 24 hours. Cells were serum deprived for ~18 to 20 hours prior to addition of 
TGF-β (2 ng/ml) for indicated time points for up to 6 hours. For signalling inhibition 
experiments LY294002 (10 µM) was added 30 minutes prior to TGF-β addition. 
Following treatments, cells were washed 2 times with ice cold PBS and fixed with 4% 
(w/v) Paraformaldehyde/PBS at 4°C for 30 minutes, with one change in fixative at 15 
minutes. Cells were washed 2 times with PBS for 5 minutes each and permeabilized using 
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0.1% Triton X-100 for 2 minutes at room temperature. Cells were then washed twice with 
PBS and blocked for 1 hour at room temperature in blocking solution [PBS, 10% (v/v) 
FCS, 10% Fish Gelatin (w/v), 5% (v/v) normal goat serum, 0.02% (w/v) Sodium Azide].  
FoxO1 (C29H4; Cell Signalling #2880) and p27Kip1 (sx53G8.5; Cell Signalling #3698) 
primary antibodies diluted in blocking solution were added to slides and incubated 
overnight at 4°C. The following day slides were washed 5 times for 5 minutes each in 
PBST.  FoxO1 slides were incubated for 1 hour at room temperature in mouse 
conformation specific anti-rabbit IgG (Cell Signalling Technology, Danvers, MA, USA) 
diluted in antibody dilution solution (1:400), followed by 2 washes for 5 minutes each in 
PBST. In order to detect FoxO1, an extra amplification step was used, slides were 
incubated in the dark for 30 minutes at room temperature in a combination of anti-rabbit-
Rhodamine X and anti-mouse-Rhodamine X (Jackson Immunoresearch Laboratories, 
West Grove, PA, USA) diluted in blocking solution (1:300), followed by 5 washes for 5 
minutes each in PBST. p27Kip1 slides were incubated for 30 minutes at room temperature 
in mouse-AlexaFluor488 (LifeTechnologies; Carlsbad, CA, USA) diluted in antibody 
dilution solution (1:300), followed by 5 washes for 5 minutes in PBST. FoxO1 and 
p27Kip1 slides were coverslipped with Vectashield (Vectorlabs, Burlingame, CA, USA). 
Cellular localization was visualized by fluorescence microscopy (DMIRII; Leica 
Microsystems, Wetzlar, Germany) with Openlab image acquisition software or confocal 
microscopy (Olympus, Tokyo, Japan).   
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2.4 Quantitative RT-PCR 
AKR-2B cells were grown as per Western blotting protocols and treated with 
TGF-β (2 ng/ml) up to 6 hours. LY294002 (10 µM) in DMSO was added 30 minutes 
prior to TGF-β addition. Following TGF-β addition, cell media was aspirated and washed 
with ice cold PBS. RNeasy Plus mini prep kits (Qiagen Inc., Toronto, ON, Canada) were 
used to extract cellular RNA from fibroblasts as per the manufacturer’s instructions. 
Sample RNA was collected in 30 µl of RNase free water and stored at -80°C. Sample 
RNA concentrations and quality were determined with an Agilent 2100 Bioanalyser 
(Agilent Technologies, Waldbronn, Germany). Sample RNA of >8.0 RIN values were 
used for analysis. The Taqman RNA to CT kit (Applied Biosystems, Foster City, CA, 
USA) was used and Taqman probe sets for p27kip1 (Mm00438168_m1) and GAPDH 
(Mm99999915_g1) were purchased from Applied Biosystems. Initially qRT-PCR was 
first performed with serial dilutions of template to determine linearity and efficiency of 
cDNA synthesis reaction.  Based on this information 0.1 µg of sample RNA was used in 
the cDNA synthesis step.  To each well of a 96 well plate, 20 µl reactions were added 
composed of; 10 µl RT PCR Mix, 0.5 µl RT enzyme mix, 0.1 µg RNA, 1µl TaqMan 
probe set and water to 20 µl. Individual samples were added to triplicate wells, for each 
probe. Plates were centrifuged at 2,000xg for 3 minutes and qRT-PCR was performed 
(Applied Biosystems, Prism 7000). GAPDH was used as an internal normalization 
control. Relative fold changes were calculated corrected for GAPDH expression levels 
using the ΔΔCT method (Pfaffl, 2001). 
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2.5 Infection of Cells with Virus 
FoxO4-EGFP was expressed as a retroviral particle via the GP2 packaging cell 
line and VSV-G coat protein (Clontech, Palo Alto, CA, USA), while FoxO3a-A3-EGFP 
was expressed as an adenovirus [the generous gift of Dr. Ken Walsh, Skurk et al., 2004] 
in order to express these proteins in fibroblasts. AKR-2B cells were plated in 6 well plates 
at a concentration of 3x105 cells/well in growth medium.  Cells were allowed to attach 
over night before virus was added the next day with an MOI of 50:1 (adenovirus) or 5:1 
(retrovirus).  Medium was replaced 18 to 20 hours later with DMEM containing 0.1% 
NBCS to serum deplete cells for 18 hours. Cells were then treated with TGF-β (2 ng/ml) 
for 6 hours and either total cellular lysates or RNA was collected, as previously described.  
 
2.6 Densitometry and statistical analysis 
Western blotting images were scanned and densitometry was performed using 
Image J software. Graphpad Prism software was used to perform statistical analysis on 
western blot densitometry and qRT-PCR relative expression results. To test for significant 
differences between samples an ANOVA was performed followed by Tukey’s or 
Dunnett’s multiple comparisons test.  Significant differences were accepted at α≤0.05.
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CHAPTER 3-Results 
3.1 FoxOs are phosphorylated in fibroblasts when treated with TGF-β 
 Previous studies in the Doré lab by graduate student Kielley, D. (2008) examined 
the regulation of PI3K/Akt signalling by TGF-β, and found that in fibroblast cells TGF-β 
stimulation increased Akt phosphorylation dependent on PI3K (results not shown). These 
results suggest that TGF-β plays a role in the regulation of the FoxO group of 
transcription factors since they are downstream of Akt. To determine if TGF-β alters 
FoxO group member function I decided to first look at their phosphorylation in fibroblast 
cells following the addition of TGF-β. AKR-2B fibroblasts were treated with TGF-β1 (2 
ng/ml) over a 240-minute period, as shown in Figure 3, which demonstrates FoxO1 
phosphorylation at threonines 24 & 32 apparent at 30 minutes and increases through 240 
minutes. FoxO1 phosphorylation was significantly increased above untreated steady state 
levels (time 0) beginning at 120 minutes and continuing through 240 minutes (Figure 3B). 
Relative levels of phosphorylated protein, as measured by densitometry of immunoblots, 
were corrected for loading differences using total FoxO1.  
 There are four members of the FoxO group (FoxO1, 3a, 4 and 6; Shin et al., 2001; 
Essaghir et al., 2009), however I was only able to analyze the phosphorylation of FoxO1, 
FoxO3a and FoxO4, following TGF-β addition, since antibodies were not available for 
phosphorylation sites on FoxO6. Similar to results for FoxO1, phosphorylation of 
FoxO3a at serines 318 & 321 appears at 30 minutes and increases to 180 minutes (Figure 
4A). When corrected for loading differences using β-actin, phospho-FoxO3a levels were 
significantly above steady-state levels by 180 through 240 minutes. Although   
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Fig. 3. TGF-β induced FoxO1 phosphorylation in fibroblasts. (A) AKR-2B cells were 
treated with TGF-β (2 ng/ml) for times ranging from 0 to 240 minutes. Cell lysates were 
probed with antibodies specific to phosphor-FoxO1. Blots were stripped and reprobed for 
total FoxO1 as a loading control. (B) The mean densitometric value of (A) was used to 
quantify and evaluate changes in phosphor-FoxO1 over time using total FoxO1 as the 
loading comparative control n=4 (*represents p>0.05).   
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Fig. 4. TGF-β induced FoxO3a phosphorylation in fibroblasts. AKR-2B cells were 
treated with TGF-β (2 ng/ml) for a range of times from 0 to 240 minutes. Cell lysates 
were probed with an antibody specific to (A) phosphor-FoxO3a and (C) phosphor-
FoxO1/3a. Blots were stripped and reprobed for (A) β-actin and (C) total FoxO1 as a 
loading control. The mean densitometric value of (A) and (C) was used to quantify and 
evaluate changes in phosphor-FoxO3a using (A) β-actin and (C) FoxO1 as the loading 
comparative control n=4 (*represents p>0.05 and *** represents p>0.001).  
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phosphorylation of serines 318/321 of FoxO3a is necessary for its nuclear exclusion. 
Figure 4B shows an increase of phosphorylated FoxO3a over 240 minutes at threonine 
32, the Akt phosphorylation site. Utilizing the difference in molecular masses of FoxO3a 
and FoxO1 and the cross-reactivity of the antibody for the phospho-threonine motif, I was 
able to use total FoxO1 protein as the loading control for both FoxO1 and FoxO3a to 
determine the phosphorylation of FoxO3a was significantly increased above steady-state 
levels by 180 and 240 minutes.  This data demonstrates that TGF-β regulates Akt directed 
phosphorylation of FoxO3a and that the kinase phosphorylates the S318/321 site.  
 In addition, I show that like the FoxO1 and FoxO3a members of the subfamily, 
FoxO4 is phosphorylated in response to TGF-β treatment (Figure 5A, B). 
Phosphorylation of FoxO4 was significantly increased above steady-state levels by 180 
minutes when corrected for loading differences using β-actin. There was a slight decrease 
of p-FoxO4 at 240 minutes, however, insignificant compared to steady state levels.  
 
3.2 PI3K and Akt regulation of FoxO1 phosphorylation 
 Having established that TGF-β stimulates the phosphorylation of three members 
of the FoxO family at Akt sites, my next step was to determine if the mechanism was via 
the known PI3K/Akt pathway. Using small molecular weight inhibitors and FoxO1-
Thr24-phosphorylation as a marker of TGF-β/Akt activity I analyzed the effect inhibition 
of Akt or TGF-β on phosphorylation of FoxO1 would be. Figure 6 (A and B)  
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Fig. 5. TGF-β induced FoxO4 phosphorylation in fibroblasts. (A) AKR-2B fibroblasts 
were treated up to 240 minutes with TGF-β (2 ng/ml). Cell lysates were probed with an 
antibody specific to phosphor-S193-FoxO4. Blots were stripped and reprobed for β-actin 
as a loading control. (B) The mean densitometric value of (A) was used to quantify and 
evaluate change in phosphor-S193-FoxO4 overtime using β-actin as the loading 
comparative control n=3 (*represents p<0.05).  
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 1	  
 2	  
Fig. 6. TGF-β, PI3K and Akt aid in the regulation of FoxO1 phosphorylation in 3	  
fibroblasts. (A) AKR-2B fibroblasts were untreated, treated with TGF-β (2 ng/ml) for 4	  
240 minutes, treated with the PI3K inhibitor LY294002 (10 µM) for 30 minutes, or 5	  
treated with LY294002 (10 µM) 30 minutes prior to TGF-β (2 ng/ml) addition for 240 6	  
minutes. Cell lysates were probed with an antibody specific to phsopho-FoxO1. Blots 7	  
were stripped and reprobed for total FoxO1as a loading control. (B) AKR-2B fibroblasts 8	  
were treated as per (A) in the first 4 lanes, with additional treatments of an Akt inhibitor 9	  
AKTVIII (1µM) or a TGF-β inhibitor LY364947 (0.5 µM) alone for 30 minutes or in 10	  
addition to TGF-β (2 ng/ml) for 240 minutes. Cell lysates were probed for an antibody 11	  
specific to phospho-FoxO1. Blots were stripped and reprobed for total FoxO1 as a 12	  
loading control n=3.   13	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shows an increase in FoxO1 phosphorylation following TGF-β addition, as previously 
shown. With the addition of LY294002 (PI3K inhibitor), Akt VIII (Akt1 and 2 isoform 
specific inhibitor) and LY364947 (Type I receptor kinase inhibitor) the phosphorylation 
of FoxO1 was negated. This demonstrates that FoxO1 T24 phosphorylation is regulated 
by TGF-β via the PI3K/Akt pathway in fibroblast cells. 
   
3.3 Immunolocalization of FoxO1 
 As described in the literature, phosphorylation of FoxO members by Akt and other 
kinases correlates with the shuttling of FoxO members from nucleus to cytoplasm (van 
der Heide et al., 2004) as part of their functional inactivation. Since I found that FoxO 
members are being phosphorylated following TGF-β addition via PI3K/Akt, I 
hypothesized that FoxO members are also being shuttled from nucleus to cytoplasm. To 
investigate whether this was occurring, we treated fibroblasts with TGF-β.   
AKR-2B cells were treated up to 360 minutes with TGF-β1 (2 ng/ml).  Since I 
showed that the three common FoxO members were all phosphorylated by TGF-β 
addition (Figures 3,4,5), I used FoxO1 as an indicator for the FoxO family since 
antibodies were available for this member that worked in 
immunocytochemistry/immunofluorescence. Total FoxO1 was detected by 
immunofluorescence, and visualized by confocal microscopy. Figure 7A shows FoxO1 is 
localized to the nucleus in senescent, untreated fibroblasts.  Over the course of 360 
minutes of TGF-β treatment I show a progressive movement of FoxO1 from the nucleus  
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Fig. 7. FoxO1 in vitro cytoplasmic localization following TGF-β addition. AKR-2B 
fibrobasts were (A) untreated and treated with TGF-β (2 ng/ml) for (B) 120 minutes, (C) 
240 minutes and (D) 360 minutes. Cells were incubated with FoxO1 antibody, detected 
with Rhodamine X conjugated secondary antibody, and visualised by confocal 
microscopy n=3.  
	   37	  
into the cytoplasm.  Colocalization of FoxO1 with a TOPRO nuclear stain was used to 
verify that FoxO1 was nuclear localized (results not shown).  Taken together these results 
suggest that TGF-β regulates not only FoxO member’s phosphorylation, but also 
subcellular localization in fibroblasts.  
To determine whether the previously demonstrated PI3K-Akt pathway directs the 
relocalization of FoxO1, after the addition of TGF-β, I inhibited PI3K with the addition of 
LY294002. Figure 8 shows the redistribution of FoxO1 to the cytoplasm induced by 
TGF-β addition (Figure 8B) is inhibited by co-incubation with LY294002 and TGF-β 
(Figure 8D). Taken together, these results support my previous results that in fibroblast 
cells, TGF-β regulates FoxO member subcellular localization and does so via the PI3K 
pathway.   
 
3.4 TGF-β regulation of p27kip1 
p27kip1 is a tumor suppressor protein that inhibits the cell cycle (Dijkers et al., 
2000). Akt induces phosphorylation of p27kip1, and is thought to be one of the primary 
mechanisms cells use to inhibit p27kip 1 actions (Blagosklonny, 2002). As I previously 
show, Akt activation by TGF-β results in FoxO family members being inactivated by 
phosphorylation and their nuclear exclusion. Within the nucleus, active FoxO members 
induce the expression of p27kip1 (Dijkers et al., 2000; Shin et al., 2002). Thus by 
activating Akt, I hypothesized that TGF-β is involved in the negative regulation of 
p27kip1, both at the transcriptional and post-translational levels, in fibroblasts. To test this, 
TGF-β1 (2 ng/ml) was added to AKR-2B cells in a time dependent manner. Figure 9 
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1	  
Fig. 8. PI3K aids in the localization of FoxO1 following TGF-β addition in vitro. 2	  
AKR-2B fibroblasts were (A) untreated, (B) treated 240 minutes with TGF-β (2 ng/ml), 3	  
(C) treated with PI3K inhibitor LY294002 (10 µM), and (D) LY294002 treatment 30 4	  
minutes prior to TGF-β (2 ng/ml) addition for 240 minutes. Cells were incubated with 5	  
total FoxO1 antibody, detected using Rhodamine X conjugated secondary antibody and 6	  
visualised by confocal microscopy n=3.  7	  
	   39	  
 
Fig. 9. p27kip1 is phosphorylated in fibroblasts following TGF-β treatment. (A) AKR-
2B fibroblasts were treated with TGF-β (2 ng/ml) for times ranging from 0 to 360 
minutes. Cell lysates were probed with an antibody specific to phosphor-p27kip1. Blots 
were stripped and reprobed for total p27kip1 as a loading control, and stripped a second 
time and reprobed for β-actin as a secondary control. (B) The mean densitometric value 
of phosphor-p27kip1 in (A) was used to evaluate changes in phosphor-p27kip1 over time 
using total p27kip1 as a comparative control (C) The mean densitometric value of total 
p27kip1 in (A) was used to show no change in total p27kip1 expression over time using β-
actin as a comparative control n=3 (*=p>0.05, **=p>0.01, ***=p>0.001).   
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shows phospho-T198-p27kip1 being detectable at 60 minutes and increasing up to 240 
minutes when compared to total p27kip1, with significant increased levels above steady 
state by 120 and 240  minutes. Interestingly I noted a significant decrease in phospho-
T198-p27kip1 from 240 minutes to 360 minutes of TGF-β treatment.  Phosphorylation of 
p27kip1 at T198 has been associated with protein stability; therefore by usingβ-actin as a 
secondary control I assessed total p27kip1 protein levels relative to total cellular protein. 
Although not significantly different, the levels of total p27kip1 were reduced by 
approximately 0.25 fold from steady state levels by 240 and 360 minutes of TGF-β 
treatment. 
 The next step was to identify if the phosphorylation of p27kip1, following TGF-β 
addition, was associated with shuttling p27kip1 from the nucleus to the cytoplasm. Total 
p27kip1 was visualized using immunofluorescence following TGF-β (2 ng/ml) addition. 
Figure 10A shows p27kip1 to be localized primarily in the nucleus in serum depleted, 
senescent, untreated AKR-2B fibroblasts. Similar results are seen after 120 minutes of 
TGF-β treatment (Figure 10B). By 240 and 360 minutes of TGF-β addition, Figure 10C, 
D shows the majority (approximately 90%) of p27kip1 to be found within the cytoplasm.  
 
3.5 Target gene regulation by FoxO transcription factors 
FoxO is a family of transcription factors that regulate expression of genes 
including p27kip1 (Dijkers et al., 2000; Shin et al., 2002). From previous data I showed 
that TGF-β induced the phosphorylation of the three common FoxO members and nuclear 
exit of FoxO1, suggesting that by removing FoxO members from the nucleus, TGF-β   
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Fig. 10. p27kip1 becomes localized to the cytoplasm in fibroblasts following TGF-β 
addition in vitro. AKR-2B fibroblasts were (A) untreated and treated with TGF-β  
(2 ng/ml) for (B) 120 minutes, (C) 240 minutes and (D) 360 minutes. Cells were 
incubated with an antibody specific for total p27kip1, detected using Alexafluor 488 and 
visualised by fluorescent microscopy. DMSO was used as a negative control (E) and (F) 
n=3. 1	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would inhibit their nuclear functions as well. I tested this hypothesis by examining if 
TGF-β affected p27kip1 transcription in fibroblasts. mRNA expression of p27kip1 was 
measured following time-dependent addition of TGF-β to AKR-2B cells. qRT PCR, using 
probes specific for p27kip1, demonstrated a TGF-β induced a decrease of p27kip1 mRNA 
expression over time. A significant decrease in expression was seen by 240 minutes 
continuing through 360 minutes (Figure 11A).  
To determine if the TGF-β induced reduction in p27kip1 mRNA expression was 
actually regulated by the PI3K pathway, I used LY294002 to inhibit PI3K. Fibroblasts 
were untreated, treated with TGF-β only, LY294002 only and both TGF-β and LY294002 
for 360 minutes. qRT-PCR measured p27kip1 expression and its relative fold change was 
calculated using GAPDH mRNA as an internal standard. I found a significant decrease in 
p27kip1 expression from cells treated with TGF-β for 360 minutes (Figure 11B), relative to 
untreated, similar to that seen previously in Figure 11A. Although reduced, fibroblasts 
treated with LY294002 showed no significant difference in p27kip1 expression relative to 
either untreated fibroblasts or cells treated with TGF-β. Interestingly, fibroblasts treated 
with both TGF-β and LY294002 showed no significant change in p27kip1 expression when 
compared fibroblasts treated with only LY294002.  
Additionally, AKR-2B cells were infected with viruses containing an EGFP-
FoxO4 fusion protein or an EGFP-FoxO4/AFX-A3 fusion protein (A3), where the three 
Akt phosphorylation sites are mutated and therefore cannot be inactivated. The expression 
of p27kip1 was then measured using qRT-PCR. Figure 12A shows the relative fold change   
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Fig. 11. TGF-β and PI3K regulation of p27kip1 RNA expression in fibroblasts.  
(A) AKR-2B fibroblasts were treated with TGF-β (2 ng/ml) for 0 to 360 minutes. Cellular 
RNA was collected and qRT-PCR was performed using TaqMan probes specific for 
p27kip1 and GAPDH as an internal control. (B) AKR-2B fibroblasts were untreated, 
treated with TGF-β (2 ng/ml) for 360 minutes, treated with the PI3K inhibitor LY294002 
(10 µM) for 30 minutes or treated with LY294002 (10 µM) for 30 minutes prior to TGF-β 
addition for 360 minutes. Cellular RNA was collected and qRT-PCR was performed as 
per (A). Both (A) and (B) were performed in triplicates on 3 or 4 independent 
experiments respectively. Relative fold changes were calculated and corrected for 
GAPDH expression levels using the ΔΔCT method (*=p>0.05, **=p>0.01).  
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Fig. 12. p27kip1 RNA expression following TGF-β addition in mutant infected 
fibroblasts. Normal AKR-2B fibroblasts and AKR-2B fibroblasts infected with an 
adenovirus containing a FoxO4-EGFP fusion protein or an A3-EGFP (3 mutated Akt 
phosphorylation sites) fusion protein was untreated or treated with TGF-β (2 ng/ml) for 
360 minutes. Cellular RNA was collected and qRT-PCR was performed using TaqMan 
probes specific for p27kip1 and GAPDH as an internal control. Relative fold changes were 
calculated and corrected for GAPDH expression levels using the ΔΔCT method. 
Experiments were performed in triplicates on 3 independent experiments. (A) shows that 
there was no significant relative fold change in p27kip1 expression in infected untreated 
fibroblasts compared to normal untreated fibroblasts. (B) Relative fold change in RNA 
expression of p27kip1 in TGF-β treated fibroblasts compared to untreated fibroblasts 
within the same infection type (*=p>0.05, **=p>0.01).  
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of p27kip1 in wild type or FoxO4-A3 mutant infected, untreated fibroblasts compared to 
normal untreated AKR-2B cells to demonstrate there was no significant change in 
expression of p27kip1 between untreated cells regardless of expression construct. Figure 
12B shows the expression of p27kip1 in AKR-2B cells treated with TGF-β compared to 
untreated fibroblasts expressing the same FoxO4 construct. The expression of p27kip1 in 
normal AKR-2B cells treated with TGF-β decreased significantly compared to normal 
untreated cells. Similarly, p27kip1 expression was significantly decreased in FoxO4-EGFP 
expressing TGF-β treated fibroblasts when compared to untreated infected cells. 
Interestingly, when AKR-2B cells expressed the A3 mutant of FoxO4 and treated with 
TGF-β they also significantly decreased expression of p27kip1, compared to untreated A3-
EGFP expressing fibroblasts.  
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CHAPTER 4-Discussion 
 
4.1 FoxO regulation by TGF-β in fibroblasts 
There is growing evidence that TGF-β mediates the regulation of several cellular 
target pathways outside of the canonical Smad pathway (Wilkes et al., 2005; Hough et 
al., 2012; Bakin et al., 2000; Hong et al., 2011; Katz et al., 2013; Miyazono et al., 2012; 
Suzuki et al., 2007; Yi et al., 2005), however the complete picture is still not well-
defined. There is a definitive understanding that the effect of TGF-β is cell type specific. 
In epithelial, endothelial and hematopoietic cells, TGF-β inhibits cellular proliferation, 
while in fibroblasts, TGF-β induces cellular proliferation (Massagué, 2008; Shin et al., 
2001). Much is still unknown about the downstream targets of TGF-β regulation within 
different cell-types, or whether these target pathways are actually smad-independent. 
Wilkes et al., 2005 found that TGF-β regulated the Pak2 pathway independently of 
Smads, but only in fibroblasts and not in epithelial cells, and this was dependent on PI3K. 
Previous studies from the Doré lab and others (Bakin et al., 2000; Hong et al., 2011; 
Hough et al., 2012; Kato et al., 2006; Miyazono et al., 2012; Wilkes et al., 2005; Yi et 
al., 2005) reported that TGF-β activates the PI3K/Akt pathway. Since FoxOs are 
downstream of Akt, and FoxOs are transcription factors involved in the activation of 
target genes responsible for cell death or cellular proliferation/inhibition, I chose to look 
at TGF-β post-translational regulation of FoxOs by phosphorylation in fibroblasts. 
Phenotypically normal fibroblasts were treated with TGF-β for a range of times up 
to 240 minutes. FoxO1, FoxO3a, and FoxO4 showed an increase in phosphorylation over 
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time at sites known to be phosphorylated by Akt (Figures 3, 4, and 5). These results are 
consistent with the well-known receptor tyrosine kinase activated PI3K/Akt signalling 
pathway, in that activated Akt phosphorylates FoxOs (Tzivion et al., 2011; Carracedo and 
Pandolfi, 2008; Yi et al., 2005). This indicates that TGF-β regulation of FoxOs in 
fibroblasts follow a similar pathway as the RTK cellular signalling pathway.  
 As previously mentioned, the phosphorylation of FoxO’s by Akt on specific sites 
(T32, S253, S315; relative to FoxO3a) results in its removal from the nucleus (Shin et al., 
2001). In Figure 4a, I show that the phosphorylation of FoxO3a on serines 318/321 
(responsible for the nuclear export of FoxO) when treated with TGF-β. A study by Rena 
et al. 2002, showed that following the phosphorylation of serine 318 by Akt, serine 321 
can be phosphorylated by CK1, another known negative regulator of FoxO’s, and is 
dependent on PI3K (Rena et al., 2002).   Although the antibody used in this study is 
unable to differentiate between the phosphorylation sites, it is interesting to note that 
TGF-β treatment increased the phosphorylation of FoxO3a at these alternative 
phosphorylation sites and with further investigation might show that TGF-β can regulate 
FoxO3a by CK1.  
To ensure that my findings are PI3K/Akt and TGF-β dependent, and that another 
mechanism is not regulating FoxO, I inhibited PI3K, TGF-β receptor and Akt using 
chemical inhibitors. I found that FoxO1 was not phosphorylated, even when TGF-β was 
added (Figure 6).  Kato et al. 2006 previously found similar findings to my study using 
kidney mesangial cells. When cultured mesangial cells were treated with TGF-β they 
found significantly increased levels of p-Akt and p-FoxO3a, that were abrogated when 
treated with the same PI3K inhibitor (Kato et al., 2006). Mesangial cells are found within 
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the kidney and there is evidence that they originated from mesenchyme, the same 
embryonic origin as fibroblasts (Faa et al., 2012). Similarly, Kurebayeshi et al. 2016 
found that in CD4+ T-cells, TGF-β induced Akt phosphorylation dependent on PI3K 
resulting in the phosphorylation and inhibition of FoxO1 and FoxO3a transcription 
factors. Although different types of cells were used in these studies (Kurebayeshi et al., 
2016; Kato et al., 2006), they demonstrate TGF-β regulation of a FoxO family member 
dependent on the PI3K/Akt family and corroborates my findings that TGF-β regulates 
FoxO in a PI3K/Akt dependent manner.  
 
4.2 FoxOs are localized to the cytoplasm following TGF-β stimulation 
FoxO regulation is dependent on the specific regulator involved and type of 
modification (Huang and Tindall, 2007). The phosphorylation of FoxOs by Akt on (T32, 
S253, S315; numbered relative to FoxO3a), results in the inactivation and the removal of 
FoxO from the nucleus to the cytoplasm, by 14-3-3, where it is unable to bind to target 
transcription sites (Carter and Brunet, 2008; Essaghir et al., 2009; Greer and Brunet, 
2005; Huang and Tindall, 2007; Shin et al., 2001; van der Heide et al., 2004). Since I 
have shown that Akt is phosphorylating FoxO, I wanted to visualize the movement of 
FoxO from nucleus to cytoplasm following TGF-β addition over time. Figure 7 shows 
that FoxO1 moved from the nucleus to the cytoplasm following TGF-β addition over 360 
minutes. I chose to look at FoxO1 specifically, because the antibodies for this member 
had the capability for immunofluorescence. Although, I did not show that FoxO3a and 
FoxO4 are undergoing nuclear-cytoplasmic shuttling in this study, I can infer similar 
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results, since there is evidence in the literature that FoxO3a and FoxO4 do in fact move 
from nucleus to cytoplasm when phosphorylated on known Akt phosphorylation sites 
(Kato et al., 2006; Brownawell et al., 2001) , as was shown in Figures 4 and 5. To ensure 
that the regulation of FoxO1 subcellular localization is PI3K/Akt dependent I used 
LY294002 to inhibit PI3K and I found that FoxO1 remained localized only to the nucleus 
(Figure 8).   
As previously discussed, there are some contrasting views in the literature 
regarding Smad-independent TGF-β pathways. There are indications that in some cases 
there is a cross talk between the Smad pathway and the FoxO pathway. In 2004, Seoane 
et al., published a study where they showed that TGF-β induced binding of FoxO3a with 
Smads 3/4 to the p21cip1/waf1 promoter site within the nucleus in HaCaT epithelial cell 
lines. Coimmunoprecipitation experiments showed that FoxO1, O3, O4 were bound to 
Smad 3 and Smad 4 in HaCaT cells following TGF-β addition (Seoane et al., 2004). My 
study would suggest that in fibroblast cells, TGF-β regulates the PI3K/Akt pathway in a 
Smad-independent manner, since addition of TGF-β resulted in the phosphorylation and 
removal of FoxO from the nucleus, and therefore could not be bound to Smads at 
promotor sites. This could also provide insight for why TGF-β regulation is dependent on 
cell type.  
4.3 p27kip1 is phosphorylated and localized to the nucleus following TGF-β addition 
p27kip1 regulates the cell cycle by binding to cdk-cyclin complexes and hinders 
cell cycle progression (Dijkers et al., 2000; Reynisdottir et al., 1995). p27kip1 can be 
regulated post-translationally and at the gene expression level.  On a post-translational 
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level, when p27kip1 is phosphorylated by Akt, like FoxO, it is targeted by 14-3-3 and 
moved to the cytoplasm (Liang et al., 2002; Shin et al., 2002; Motti et al., 2004), where it 
is unable to bind cyclin-cdk complexes, and therefore would allow cell cycle to progress.  
Since Akt is activated in fibroblasts by TGF-β, as was found in previous studies in the 
Doré lab, we would expect to also see p27kip1 being phosphorylated over time. Fibroblasts 
were treated with TGF-β, as per previous experiments and there was an increase in p-
T198-p27kip1 after TGF-β addition (Figure 9). It is important to note that there was a 
decrease in phosphorylation from 240-360 minutes. It can be ruled out that it is not due to 
turnover of p27kip1, as there was no change in total p27kip1 over time. Sun et al., (2016) 
has found that the phosphatase PPM1G dephosphorylates p27kip1 at T198 (the same 
phosphorylation site as Akt), and could be the reason for the decrease in phosphorylation 
of p27kip1 at 360 minutes.  In contrast, the same report found that phosphorylated p27kip1 
had declined to undetectable amounts at just 2 hours. It is important to note that they used 
HeLa cells (an immortalized transformed cancer cell line) for this specific experiment and 
cells were not stimulated by specific growth factors. Instead, serum containing culture 
media was used to release cells from senescence. Given the differences in methodology, it 
would be difficult to assume that PPM1G is involved here without doing the required 
experiments.   
Much like the FoxO family, Akt phosphorylated p27kip1 is targeted by 14-3-3 and 
is removed from nucleus to cytoplasm.  Since p27kip1 was phosphorylated over time with 
TGF-β addition, I would expect to see p27kip1 move from the nucleus to the cytoplasm 
over time.  Consistent with the time line found in my western blots of p-p27kip1, at 240 
minutes, p27kip1 was localized to the cytoplasm in comparison to untreated cells (Figure 
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11). At 360 minutes we still see the majority of cells having p27kip1 located in the 
cytoplasm, with some cells showing its remaining localization in the nucleus. The 
movement of p27kip1 into the cytoplasm would indicate cell cycle progression, as it is 
incapable of binding cyclin-cdk complexes outside of the nucleus.   
 A study by Ciarallo et al., (2002), found that TGF-β modulated the 
phosphorylation of p27kip1 from binding Cyclin D1 to binding and inhibiting the Cyclin 
E1-cdk2 complex in a human epithelial cell line that is resistant to TGF-β mediated G1 
arrest. Although this was completed in a different cellular context, it does suggest that 
TGF-β may regulate p27kip1, or supports the idea that an epithelial cell type that gains 
TGF-β resistance may be doing so by activating a fibroblast phenotype, ie EMT. To my 
knowledge this would be the first study to suggest that TGF-β may regulate the 
phosphorylation of p27kip1 dependent on PI3K/Akt in any cell context.  
 
4.4 TGF-β regulates p27kip1 gene expression in fibroblasts  
As previously mentioned, p27kip1 is also regulated on the gene expression level by 
transcription factors binding to its promoter site, and studies have found that p27kip1 
mRNA and protein are elevated following FoxO activation (Dijkers et al., 2000). 
Furthermore, there are FoxO binding consensus sequences within the p27kip1 promoter 
(Dijkers et al., 2000).  Although there is much evidence that FoxOs are involved in the 
transcriptional regulation of p27kip1, there is little evidence to suggest that TGF-β 
regulates p27kip1 directly at the gene expression level.  Microarray studies showed that 
p21cip1, but not p27kip1, was increased in HaCaT epithelial cells by TGF-β (Kang et al., 
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2003; Seoane et al., 2004), but the study did not provide any insight into mesenchymal 
cells.  
Since I demonstrated that TGF-β regulates FoxOs by Akt phosphorylation and 
therefore its inactivation, I also wanted to see if there was an effect on p27kip1 mRNA 
levels after being treated with TGF-β. I found that p27kip1 mRNA expression decreased by 
240 minutes of TGF-β addition, compared to our control, with continued reduction up to 
360 minutes (Figure 11A). It is worth noting that the timing of 240 minutes is important 
since I found that FoxO phosphorylation (protein inactivation) was significantly increased 
at 120 and 180 minutes for FoxO1 and FoxO3a respectively, and that nuclear exclusion of 
FoxO1 occurred between 120 and 240 minutes of TGF-β addition. This would suggest 
that p27kip1 mRNA expression decreased coincidentally with the removal of FoxO from 
nucleus to cytoplasm, since FoxO would be unable to promote its transcription.  
Consistent with my methodology and to ensure that TGF-β is acting via the PI3K 
pathway, I inhibited PI3K by LY294002. I found that p27kip1 expression decreased 
following LY294002 treatment but was not significant when compared to the expression 
in untreated cells. I found a decrease in p27kip1 expression when cells are treated with 
LY294002 and TGF-β (Figure 11B), however, this decrease was not significant when 
compared to the expression in cells treated with LY294002 alone.   Therefore, strictly 
speaking LY294002 blocked a TGF-β induced decrease in p27kip1 expression. However, 
the difficulty in interpreting these results lies in the fact that there was inconsistency 
between our controls (untreated or LY294002). It is important to note that for this specific 
experiment, AKR-2B cultures were incubated with LY294002 for 30 minutes prior to 
TGF-β for 360 minutes, which was a longer incubation time than our other experiments 
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using LY294002. Perhaps the effect of LY294002 diminishes following such a long 
incubation time or it has a negative effect on the cells. LY294002 also stimulates 
apoptosis in cells depending on the concentration and length of incubation time (Semba et 
al., 2002); however, the concentration I used would not normally induce apoptosis and 
cells were checked prior to cellular lysis to ensure no visual signs of apoptosis.  
Alternatively, since PI3K has a large number of biological effects in addition to 
regulating Akt activation, FoxO transcription factors utilize a number of co-factors in 
regulating gene expression (Katso et al., 2006). It is also reasonable to assume that 
inhibition of one of these PI3K dependent co-factors decrease p27kip1 expression 
independent of FoxO. In this case it is difficult to assume that the decrease in p27kip1 
mRNA expression is a result of a decrease in the ability of FoxO to promote p27kip1 
transcription following TGF-β stimulation.  
 Last, I looked at p27kip1 mRNA expression following TGF-β addition in normal 
AKR-2B fibroblasts expressing FoxO4-EGFP fusion protein or an A3-EGFP fusion 
protein (constitutively active FoxO4) to gain an additional understanding of the role of 
TGF-β regulation of p27kip1 via FoxO4 (Medema et al., 2000). Figure 12A shows that the 
steady state expression of p27kip1 mRNA was consistent among all three cell culture 
types, indicating no specific baseline effect was noted for any of the FoxO4 constructs. 
Consistent with my previous results, I found that p27kip1 expression decreased following 
TGF-β addition in normal fibroblasts, as well as fibroblasts containing each FoxO4-EGFP 
fusion proteins.  The fibroblasts containing the constitutively active FoxO4-EGFP protein 
also decreased expression of p27kip1 mRNA expression following TGF-β addition. This is 
contradictory of what I expected to see since constitutively active FoxO4 should not be 
	   54	  
phosphorylated, and should therefore remain in the nucleus and be capable of 
transcription.  A study by Medema et al., (2000) used the same A3-FoxO4-EGFP found 
that FoxO4 did regulate the transcription of p27kip1, suggesting that my results are not due 
to an issue regarding the ability of FoxO4 to regulate p27kip1 transcription, but would 
suggest that FoxO4 is not involved in TGF-β regulated p27kip1 mRNA expression in 
fibroblasts.  Keep in mind that Medema et al., used A14 cells (NIH3T3 overexpressing 
insulin receptor) and cells were stimulated with insulin. Furthermore, my results do not 
mean that FoxO1 or FoxO3a are not regulating the expression of p27kip1 by TGF-β, as 
there are still endogenous levels of these FoxO members. Further studies looking at 
FoxO1 or FoxO3a TGF-β regulated p27kip1 gene expression would be ideal to determine 
the contribution of each member of the FoxO family. This suggests that TGF-β does not 
regulate the expression of p27kip1 by FoxO using some other PI3K/Akt dependent method, 
or that all FoxOs do not functionally overlap. Taken into account that when treated with a 
PI3K inhibitor I found a decrease in p27kip1 gene expression as well (Figure 11), it is 
possibly the former explanation. However, since I show that TGF-β does cause Akt-
dependent, inactivating phosphorylation of FoxO1, 3A and 4, as well as nuclear exclusion 
of FoxO1 and a large body of evidence supports FoxO regulation of p27kip1 expression, 
more information using specific selective inhibition is needed before this explanation 
should be accepted.  
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4.5 Future directions  
 The data from this study provide an indication that TGF-β can regulate FoxO 
family members dependent on the PI3K/Akt pathway in fibroblast cells. However, there 
are still questions to be answered regarding this TGF-β non-canonical pathway. 
I would like to highlight some experimental additions and fine-tuning I would 
make to this study. At the time of this study, antibodies for all FoxO family members did 
not exist, as per use of FoxO1 and 3a (T32/T34) antibodies in Figure 4 and β-actin as a 
control for FoxO4 in Figure 5. With reliable working antibodies, for all FoxO members, 
we could look at the cellular localization of FoxO3a and FoxO4 in addition to FoxO1, 
completing the full picture rather than using inference. Also, although previous studies 
from graduate students in the Doré lab show that TGF-β regulates Akt phosphorylation 
dependent on PI3K in fibroblasts, it would strengthen this study to have Akt 
phosphorylation blots alongside my FoxO phosphorylation blots.  
With regards to the cellular localization of phospho-p27kip1 , it would be 
interesting to see if the relocalization to the cytoplasm was abrogated when pre-treated 
with LY294002, to determine if the localization was dependent on PI3K.  Lastly, as my 
results could not determine if p27kip1 gene expression was regulated by TGF-β via FoxO4 
(Figure 12), it would be interesting to investigate FoxO1 and FoxO3a in the same way. 
Perhaps I would find similar results, indicating that TGF-β is regulating p27kip1 by some 
other means, or that it is only FoxO4 that is not involved in TGF-β regulated p27kip1 gene 
expression.  
One of the curious aspects of TGF-β regulation is that it is dependent on cellular 
context. As previously mentioned, in non-transformed epithelial, endothelial, and 
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hematopoietic stem cells, TGF-β inhibits cellular proliferation, and in fibroblast cells it 
induces cell proliferation (Massagué, 2008; Shin et al., 2001). In this study I only looked 
at the role of TGF-β regulation of FoxOs in fibroblast cells.  If I were to look in epithelial 
cells I would expect to see the opposite effect on FoxOs, since TGF-β inhibits cellular 
proliferation in epithelial cells. Perhaps I would not see TGF-β have an effect at all on 
FoxO. This is an important point to highlight, since TGF-β is found to have such 
contrasting roles in epithelial cells and fibroblasts. There have been studies in the 
literature regarding TGF-β regulation in epithelial cells (Shin et al., 2001; Kato et al., 
2006), however these are controversial because the cell lines that are being used in some 
studies are immortalized or cancer cells and not normal epithelial cells. In this case these 
cells are acting more similarly to fibroblasts. It would be important to ensure that these 
cells have not undergone EMT and therefore wouldn’t give an appropriate representation 
of epithelial cells response to TGF-β. 
Since the completion of the experiments in this thesis, new modern day techniques 
and technology have developed, and the use of some of these could provide novel 
findings to further this area of study. RNA-sequencing is a method used to measure the 
presence and quantity of RNA at a given point of time. This is an important technique 
used in discovery experiments to provide a global read-out of all RNA. If I used this 
technique to look at fibroblast cells prior to TGF-β treatment and those following 
treatment of TGF-β and focused on the differences of the two, it could provide us with a 
list of potential gene targets of TGF-β regulation. This list could include targets via the 
Smad pathway or other pathways, and further evaluation would be required, however, it 
would be an excellent starting point.  
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ChIp-sequencing is a method used to analyze protein interactions with DNA at 
specific moments of time. This would be an effective technology to utilize for verification 
of the binding of all or individual FoxOs to the p27kip1 promotor site prior and following 
TGF-β. As this technique shows the global DNA binding interactions, the potential of 
utilizing this technique could also highlight novel targets of FoxOs regulated through 
TGF-β. If you looked at FoxO DNA interactions before the addition of TGF-β and 
compared it to the absence or addition of new interactions after TGF-β treatment, it could 
provide us with new gene targets. This list could then be cross-referenced with the RNA-
sequencing list for a more concise list of targets for qRT-PCR to evaluate gene expression 
regulation by TGF-β/PI3K/FoxO.  
  
4.6 Summary 
 The main purpose of this study was two-fold; to determine if TGF-β regulates the 
FoxO group of transcription factors post-translationally, via the PI3K/Akt pathway in 
fibroblasts, and to determine if TGF-β regulates FoxO group functionality through 
transcription and post-translational modifications of p27kip1 in fibroblasts. Here I show 
that following TGF-β treatment; FoxO1, FoxO3a and FoxO4 are phosphorylated over 
time in AKR-2B fibroblast cells in response to TGF-β stimulation. Treatment with a 
PI3K, Akt and TGF-β inhibitors negated the phosphorylation of FoxO1, suggesting that 
TGF-β regulates FoxOs dependent of PI3K/Akt. The phosphorylation of FoxOs by Akt 
typically results in the localization from nucleus to cytoplasm, and I show here that 
FoxO1 does in fact relocate from nucleus to cytoplasm following TGF-β treatment and 
their effect was negated when treated with the PI3K inhibitor LY294002 further 
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supporting the hypothesis that FoxO group cellular localization, following TGF-β 
stimulation, is dependent on PI3K/Akt.  
 In fibroblast cells, TGF-β is known to induce cellular proliferation (Shin et al., 
2001). p27kip1 is a cyclin-dependent kinase inhibitor which binds to cyclin/cdk complexes 
and halts cell cycle progression (Dijkers et al., 2000; Reynisdottir et al., 1995; Roy and 
Banerjee, 2015). FoxOs are transcription factors known to regulate p27kip1 when active in 
the nucleus (Dijkers et al., 2000; Shin et al., 2002). Since, I found that FoxOs were 
phosphorylated, and therefore inactive following TGF-β addition in fibroblasts, I wanted 
to see if this would affect the gene expression of p27kip1 downstream of FoxO. I was able 
to show that fibroblast cell cultures treated with TGF-β decreased p27kip1 mRNA 
expression over time. However, when I treated cultures with LY294002, I was unable to 
show that the regulation of p27kip1 mRNA expression was dependent on PI3K. I was also 
unable to show conclusively that TGF-β regulates p27kip1 gene expression dependent on 
FoxO4. When AKR-2B cells expressed a FoxO4-EGFP fusion protein that is 
constitutively active and treated with TGF-β, p27kip1 gene expression was reduced similar 
to normal AKR-2B cells. It is unclear whether this result is due to the fact that TGF-β 
does not regulate p27kip1 gene expression through FoxOs in fibroblasts, or that this down-
regulation is due to compensation by endogenous levels of FoxO1 and FoxO3a.  
 TGF-β regulates a substantial number of biological events, and it has contrasting 
effects in epithelial and fibroblast cells. The TGF-β canonical Smad pathway is well 
studied, however, growing evidence involving TGF-β regulation of multiple different 
pathways outside of the Smad pathway, could explain its diverse regulatory effects. This 
study supplements findings that in fibroblasts, TGF-β can regulate the PI3K/Akt pathway, 
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and its downstream target FoxO members, as well as the post-translational regulation of 
p27kip1. Further verification is needed to conclude that the regulation of p27kip1 gene 
expression by TGF-β is in fact through the PI3K/Akt/FoxO pathway. Figure 13 shows a 
graphic depiction summarizing my findings and my suggested TGF-β/PI3K pathway.  
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Fig. 13. TGF-β regulation of the PI3K pathway. A simplified depiction 
summarizing my findings of the role of TGF-β on FoxO and p27kip1 in fibroblasts.   
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